Some of the world’s biggest pharmaceutical companies have been hit by a global recession and a drop in demand for their products.

But what can you do about it?

Read moreA global slump in drug sales has forced the pharmaceutical industry to scale back its investments in research and development, making it harder for it to produce and sell medicines that treat many of the same conditions as its blockbuster drugs.

The industry’s fortunes have been driven in part by two major events in recent years: the financial crisis and a surge in demand from patients for their medicines.

As a result, some major pharmaceutical companies are laying off workers, laying off senior executives and cutting back on research and other activities.

The result has been a sharp drop in the price of some of the drugs they make, and a slowdown in the pace of their development and commercialisation.

This year, for example, the price for a drug made by the world leader Pfizer fell nearly 30% as Pfizer’s share price fell.

The price for the drug made at a smaller British company, Serono, fell by nearly 10%.

Many of the companies making the drugs have been able to survive the downturn by finding ways to make more money.

But others, such as AstraZeneca, have had to cut back on investment, and are now struggling to find the money to keep going.

The Financial Times has been looking at the impact of the downturn on drug prices around the world.

The financial crisis The financial crisis of 2008 was the worst in history, but the damage was not only felt in the United States.

In Europe, the drug industry’s revenues fell by more than half in 2008 and 2009.

The financial impact was particularly severe in Europe because there were no effective measures in place to rein in the prices of the medications.

Some of the pharmaceutical companies that were hit hardest by the recession have since become much more profitable, while others have fallen behind.

This has led to a significant drop in their investments in the areas where their profits are most important.

As the financial crunch hit, the industry has been hit particularly hard by falling demand from its patients.

In some countries, patients have been paying more for drugs than their doctors are willing to pay for them.

As they try to cope, the pharmaceutical giants have been trying to find ways to keep prices down.

In the United Kingdom, for instance, the number of people who pay a high price for their medication has fallen by more that half in the past decade, according to data from the UK’s drug regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA).

It has also become harder for the companies that make the drugs to continue to develop and sell them.

The British government has introduced a number of measures to rein the sector in the wake of the financial downturn.

The UK government, which has the biggest share of the global market, is also stepping up efforts to reinstate the licence of drugmaker Pfizer.

Its latest plan is to require the company to pay back all money it has made on drugmakers’ drugs, and to create a national register of companies that have paid back the government’s money.

The move comes after the UK government paid $6.5bn in penalties to Pfizer, which had been accused of misleading patients about its medicines.

The MHRA says the move is the latest step in the government “to prevent the next financial crisis from undermining UK pharmaceuticals”.

In the US, the US Food and Drug Administration (FDA) is also trying to rein some of its drugmakers back into the market.

Last year, the FDA said it would be spending $50bn to rein them back in the US market, where demand for its drugs had fallen dramatically.

In February, the Federal Reserve began buying back about $6bn worth of stocks in pharmaceutical companies.

The Federal Reserve, which regulates the stock market, says it is making it easier for investors to get involved in pharmaceutical stocks, as long as they are not actively trading them.

But it is not clear that these efforts will have a big impact on the pharmaceutical market, which continues to be dominated by the big four drugmakers.

Drugmakers in the UK have been spending money on research, marketing and other initiatives in recent months, but some analysts have warned that the financial recession is still not over.

Follow the latest developments in the global drug trade and health sector.

What you need to know about the global pharmaceutical trade:The Financial Journal has compiled a list of the most popular drugs in use around the globe.

Some drugs have fallen from favour over the past five years.

Here are some of our most popular global drugs.

Drugs sold in the USA, UK, Canada and Australia:Glycyrrhiza glabra (Glycosyn)Glabra is a synthetic version of the malaria drug Zidovudine, used in the treatment of malaria in some parts of Africa.Glycirrh